Daewoong's Nabota approved for sale in Saudi Arabia, Ukraine

South Korea’s Daewoong Pharmaceutical Co. has obtained approval for the sale of its botulinum toxin product, Nabota, in Saudi Arabia and Ukraine.

Saudi Arabia, one of the largest markets for botulinum toxin, more commonly known as botox, in the Middle East will serve as the Korean company’s base for aggressive marketing in the region, Daewoong said on Wednesday.

It said Ukraine, the largest pharmaceutical market in Eastern Europe, will serve as its bridgehead for further increasing its botox sales across Europe.

With the latest approval in Saudi Arabia and Ukraine, Daewoong will be exporting Nabota to 58 countries.

The company said it aims to sell its botox product in over 100 countries, including China, by the end of this year.

Daewoong first unveiled Nabota in Korea in 2014.

Write to Ji-Hyun Lee at bluesky@hankyung.com
In-Soo Nam edited this article.